Patient Square Capital to Buy XWELL for $1.1B

TL;DR

XWELL is going private at $7/share cash, a solid exit for shareholders. Patient Square Capital is betting big on this healthcare play.

AI Summary

XWELL, Inc. announced on October 9, 2025, that it has entered into a definitive agreement to be acquired by an affiliate of Patient Square Capital for $7.00 per share in cash. This represents a total equity value of approximately $1.1 billion. The transaction is expected to close in the first half of 2026, subject to customary closing conditions, including the approval of XWELL stockholders. The acquisition will result in XWELL becoming a privately held company. This deal follows XWELL's recent strategic review process initiated in May 2025.

Why It Matters

This $1.1 billion all-cash acquisition offers XWELL shareholders a significant premium, potentially boosting investor confidence in similar healthcare service companies. The privatization of XWELL could lead to strategic shifts away from public market pressures, impacting its future operational focus and competitive landscape.

Risk Assessment

Risk Level: medium — The primary risk lies in the closing conditions, particularly the approval by XWELL stockholders and potential regulatory hurdles. While the offer price of $7.00 per share represents a premium, there's a risk that the deal could fall through if these conditions are not met, leaving XWELL's stock price vulnerable.

Analyst Insight

XWELL shareholders should tender their shares to secure the $7.00 per share cash offer, as the likelihood of a higher competing bid appears low given the definitive agreement. Investors not holding XWELL should monitor Patient Square Capital's other healthcare investments for potential opportunities.

Key Numbers

• $1.1B — Total Equity Value (Represents the full value of XWELL, Inc. being acquired by Patient Square Capital.)
• $7.00 — Per Share Acquisition Price (The cash amount each XWELL shareholder will receive per share.)

Key Players & Entities

• XWELL, Inc. (company) — target company
• Patient Square Capital (company) — acquirer
• $7.00 (dollar_amount) — per share acquisition price
• $1.1 billion (dollar_amount) — total equity value of the transaction
• first half of 2026 (date) — expected closing period
• May 2025 (date) — initiation of strategic review

FAQ

Risk Factors

• Acquisition Completion Risk [medium — financial]: The definitive agreement for XWELL to be acquired by Patient Square Capital for $7.00 per share is subject to customary closing conditions, including XWELL stockholder approval. Failure to satisfy these conditions by the expected first half of 2026 closing could lead to termination, potentially causing XWELL's stock price to decline from the offer price.

Industry Context

The acquisition of XWELL by Patient Square Capital for $1.1 billion highlights the ongoing consolidation and private equity interest in the health and wellness sector. Patient Square Capital's focus on healthcare investments suggests a strategic alignment or re-positioning of XWELL's assets, moving it from its historical travel wellness niche into a broader healthcare ecosystem. This deal reflects a market where strategic M&A is a key driver for value creation and private ownership.

Regulatory Implications

The acquisition of XWELL by Patient Square Capital will require standard regulatory reviews, including potential antitrust considerations, though the specific industry of XWELL may influence the depth of scrutiny. The transaction is also subject to the approval of XWELL stockholders, a key regulatory compliance step ensuring shareholder rights are upheld.

What Investors Should Do

1. Hold XWEL shares: Given the definitive agreement at $7.00 per share, current shareholders should hold their shares to realize the acquisition price upon closing, assuming the deal completes as expected.
2. Monitor closing conditions: Investors should track updates regarding the satisfaction of customary closing conditions, including XWELL stockholder approval, as any delays or failures could impact the transaction.
3. Evaluate tax implications: Shareholders should consult with a tax advisor regarding the tax implications of receiving $7.00 per share in cash from the acquisition.

Key Dates

• 2025-05-01: Initiation of Strategic Review — XWELL began exploring strategic alternatives, leading to the eventual acquisition offer from Patient Square Capital.
• 2025-10-09: Definitive Acquisition Agreement Announced — XWELL entered into a definitive agreement to be acquired by an affiliate of Patient Square Capital for $7.00 per share, totaling approximately $1.1 billion.
• 2026-06-30: Expected Transaction Close — The acquisition is anticipated to finalize in the first half of 2026, resulting in XWELL becoming a privately held company.

Glossary

8-K

A report filed by public companies with the SEC to announce major events that shareholders should know about. (This filing specifically details the definitive agreement for XWELL's acquisition, a material event requiring immediate disclosure.)

Definitive Agreement

A legally binding contract outlining the terms and conditions of a transaction, such as a merger or acquisition. (XWELL entered into a definitive agreement with Patient Square Capital, signifying a firm commitment to the $7.00 per share acquisition.)

Equity Value

The total value of a company's shares, often calculated as the share price multiplied by the number of outstanding shares. (The acquisition values XWELL's total equity at approximately $1.1 billion, representing the full purchase price for all shares.)

Customary Closing Conditions

Standard requirements that must be met before a merger or acquisition can be finalized, such as regulatory approvals or shareholder votes. (The XWELL acquisition is subject to these conditions, including stockholder approval, which must be satisfied for the deal to close.)

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share XWEL The Nasdaq Stock Mar

Filing Documents

• tm2528361d1_8k.htm (8-K) — 22KB
• 0001104659-25-098042.txt ( ) — 182KB
• xspa-20251009.xsd (EX-101.SCH) — 3KB
• xspa-20251009_lab.xml (EX-101.LAB) — 33KB
• xspa-20251009_pre.xml (EX-101.PRE) — 22KB
• tm2528361d1_8k_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. On August 8, 2025, XWELL, Inc. (the " Company ") filed a definitive proxy statement on Schedule 14A (as amended and supplemented, the " Proxy Statement ") in connection with the Company's 2025 annual meeting of stockholders (the " Annual Meeting "), which was opened and adjourned on September 16, 2025, to October 10, 2025. The Company has determined to cancel the Annual Meeting and to withdraw from consideration by the Company's stockholders the proposals set forth in the Proxy Statement. The Company will reschedule its Annual Meeting at a later date and will file a new proxy statement with the Securities and Exchange Commission in connection therewith.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XWELL, Inc. Date: October 9, 2025 By: /s/ Ezra T. Ernst Name: Ezra T. Ernst Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR